Tuesday, 08/03/2010
|
A NONMEM Population Approach to Modeling the Pharmacogenetics of Atazanavir and Ritonavir in HIV-Negative Adults
Deidre A. Kile, Colorado School of Public Health, University of Colorado Denver; Samantha MaWhinney, Colorado School of Public Health, University of Colorado Denver; Joseph E. Rower, University of Colorado, Denver; Peter L. Anderson, University of Colorado, Denver
|
Pharmacokinetics (PK) Comparability for Follow-On Biologics
Jason Liao, Merck Research Laboratories
2:25 PM
|
Optimal Designs for Pharmacokinetic Models
Holger Dette, Ruhr-Universität Bochum; Tim Holland-Letz, Ruhr-Universität Bochum
2:55 PM
|
Optimal Design in Bioequivalence Studies Analyzed with Nonlinear Mixed Effects Models
France Mentre, Universite Paris-Diderot; Thu Thuy N'guyen, Universite Paris-Diderot/INSERM; Anne Dubois, Universite Paris-Diderot/INSERM; Caroline Bazzoli, Universite Paris-Diderot/INSERM
3:20 PM
|
|